CLSN

Celsion Corporation Press Releases

$2.9399
*  
unch
unch
Get CLSN Alerts
*Delayed - data as of Feb. 27, 2015 11:08 ET  -  Find a broker to begin trading CLSN now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    CLSN Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Celsion Announces Updated Overall Survival Data from HEAT Study of ThermoDox® in Primary Liver Cancer
2/23/2015 8:00:00 AM - PR Newswire


Celsion Corporation Presents Clinical and Preclinical Data for GEN-1 IL-12 Immunotherapy in Ovarian Cancer at the Molecular Medicine TRI-Conference
2/20/2015 8:00:00 AM - PR Newswire


Celsion Corporation and myTomorrows Partner to Introduce ThermoDox® Early Access Program in Europe for Patients with Recurrent Chest Wall Breast Cancer
1/20/2015 8:00:00 AM - PR Newswire
▲24.57 % Price Change since this news event. The Volume Ratio is 1.35.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Celsion Corporation Submits DNA-based Immunotherapy Clinical Protocol to the FDA as Part of a First Line Treatment for Ovarian Cancer
1/6/2015 8:00:00 AM - PR Newswire
▲21.48 % Price Change since this news event. The Volume Ratio is 1.48.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day